argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
argenx, a global immunology company focused on developing treatments for severe autoimmune diseases, has scheduled its first quarter 2025 financial results and business update conference call for May 8, 2025.
The conference call and audio webcast will take place at 2:30 p.m. CET (8:30 a.m. ET). Investors and interested parties can access the live webcast through the Investors section of the argenx website. A replay will remain available on the website for approximately one year.
For direct participation, the company has provided international dial-in numbers for multiple countries including:
- United States: 1 888 415 4250
- United Kingdom: 44 800 358 0970
- Belgium: 32 800 50 201
- Japan: 81 3 4578 9081
argenx, azienda globale nel campo dell'immunologia specializzata nello sviluppo di trattamenti per gravi malattie autoimmuni, ha programmato la conferenza telefonica per la presentazione dei risultati finanziari del primo trimestre 2025 e l'aggiornamento aziendale per l'8 maggio 2025.
La conferenza telefonica e la trasmissione audio in diretta si terranno alle 14:30 CET (8:30 ET). Investitori e interessati potranno seguire la diretta streaming nella sezione Investitori del sito web di argenx. La registrazione resterà disponibile sul sito per circa un anno.
Per partecipare direttamente, l'azienda ha fornito numeri telefonici internazionali per diversi paesi, tra cui:
- Stati Uniti: 1 888 415 4250
- Regno Unito: 44 800 358 0970
- Belgio: 32 800 50 201
- Giappone: 81 3 4578 9081
argenx, una compañía global de inmunología enfocada en desarrollar tratamientos para enfermedades autoinmunes graves, ha programado su conferencia telefónica para los resultados financieros del primer trimestre de 2025 y la actualización empresarial para el 8 de mayo de 2025.
La llamada y la transmisión en audio por internet se realizarán a las 2:30 p.m. CET (8:30 a.m. ET). Los inversores y personas interesadas podrán acceder a la transmisión en vivo a través de la sección de Inversores del sitio web de argenx. La repetición estará disponible en el sitio por aproximadamente un año.
Para participar directamente, la empresa ha proporcionado números internacionales para varios países, incluyendo:
- Estados Unidos: 1 888 415 4250
- Reino Unido: 44 800 358 0970
- Bélgica: 32 800 50 201
- Japón: 81 3 4578 9081
argenx는 중증 자가면역 질환 치료제 개발에 주력하는 글로벌 면역학 기업으로, 2025년 1분기 재무 실적 및 사업 업데이트 컨퍼런스 콜을 2025년 5월 8일에 개최할 예정입니다.
컨퍼런스 콜 및 오디오 웹캐스트는 오후 2시 30분 CET (동부시간 오전 8시 30분)에 진행됩니다. 투자자 및 관심 있는 분들은 argenx 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 녹화 영상은 약 1년간 웹사이트에서 다시 시청 가능합니다.
직접 참여를 원할 경우, 다음 국가별 국제 전화번호를 이용할 수 있습니다:
- 미국: 1 888 415 4250
- 영국: 44 800 358 0970
- 벨기에: 32 800 50 201
- 일본: 81 3 4578 9081
argenx, une entreprise mondiale spécialisée en immunologie et dédiée au développement de traitements pour les maladies auto-immunes sévères, a programmé sa conférence téléphonique pour les résultats financiers du premier trimestre 2025 et la mise à jour commerciale le 8 mai 2025.
La conférence téléphonique et la diffusion audio en direct auront lieu à 14h30 CET (8h30 ET). Les investisseurs et parties intéressées peuvent accéder au webcast en direct via la section Investisseurs du site web d'argenx. Une rediffusion restera disponible sur le site pendant environ un an.
Pour participer directement, la société a fourni des numéros d'appel internationaux pour plusieurs pays, notamment :
- États-Unis : 1 888 415 4250
- Royaume-Uni : 44 800 358 0970
- Belgique : 32 800 50 201
- Japon : 81 3 4578 9081
argenx, ein globales Immunologie-Unternehmen, das sich auf die Entwicklung von Behandlungen für schwere Autoimmunerkrankungen spezialisiert hat, hat seine Telefonkonferenz zur Veröffentlichung der Finanzergebnisse des ersten Quartals 2025 und zum Geschäftsausblick für den 8. Mai 2025 angekündigt.
Die Telefonkonferenz und die Audio-Webcast finden um 14:30 Uhr MEZ (8:30 Uhr ET) statt. Investoren und Interessierte können den Live-Webcast über den Investor-Bereich der argenx-Website verfolgen. Eine Aufzeichnung wird etwa ein Jahr lang auf der Website verfügbar sein.
Für die direkte Teilnahme stellt das Unternehmen internationale Einwahlnummern für mehrere Länder bereit, darunter:
- Vereinigte Staaten: 1 888 415 4250
- Vereinigtes Königreich: 44 800 358 0970
- Belgien: 32 800 50 201
- Japan: 81 3 4578 9081
- None.
- None.
May 1, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When will argenx (ARGX) release Q1 2025 financial results?
How can investors access argenx (ARGX) Q1 2025 earnings call?
What time is argenx (ARGX) Q1 2025 earnings call in US Eastern Time?
Will argenx (ARGX) Q1 2025 earnings call be available for replay?
What is the dial-in number for US investors to join argenx (ARGX) Q1 2025 earnings call?
